AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Upcroft, J. A.
Right arrow Articles by Upcroft, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Upcroft, J. A.
Right arrow Articles by Upcroft, P.

Antimicrobial Agents and Chemotherapy, June 2001, p. 1810-1814, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1810-1814.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Drug Susceptibility Testing of Anaerobic Protozoa

Jacqueline A. Upcroft* and Peter Upcroft

Queensland Institute of Medical Research, Brisbane, Queensland 4029, Australia

Received 2 November 2000/Returned for modification 21 December 2000/Accepted 19 March 2001

A simple technique for routine, reproducible global surveillance of the drug susceptibility status of the anaerobic protozoa Trichomonas, Entamoeba, and Giardia is described. Data collected using this technique can be readily compared among different laboratories and with previously reported data. The technique employs a commercially available sachet and bag system to generate a low-oxygen environment and log2 drug dilutions in microtiter plates, which can be monitored without aerobic exposure, to assay drug-resistant laboratory lines and clinically resistant isolates. MICs (after 2 days) of 3.2 and 25 µM indicated metronidazole-sensitive and highly clinically resistant isolates of T. vaginalis in anaerobic assays, respectively. The aerobic MICs were 25 and >200 µM. MICs (1 day) of 12.5 to 25 µM were found for axenic lines of E. histolytica, and MICs for G. duodenalis (3 days) ranged from 6.3 µM for metronidazole-sensitive isolates to 50 µM for laboratory metronidazole-resistant lines. This technique should encourage more extensive monitoring of drug resistance in these organisms.


* Corresponding author. Mailing address: Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Phone: 61 7 3362 0369. Fax: 61 7 3362 0105. E-mail: jacquiU{at}qimr.edu.au.


Antimicrobial Agents and Chemotherapy, June 2001, p. 1810-1814, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1810-1814.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.